Ravi Kalhan, MD, MS

Panelists discuss how chronic obstructive pulmonary disease (COPD) management is evolving with personalized therapies, nonpharmacological care, and advanced treatments. Early diagnosis, adherence, and innovation offer hope for improved outcomes and quality of life.

Future Outlook in COPD

Video content above is prompted by the following:

Please share your closing thoughts about COPD management and outlook for the future.

Videos

Panelists discuss how key nonpharmacological interventions include vaccinations to prevent infections, pulmonary rehabilitation to improve function, and lung cancer screening for high-risk patients to enable early detection.

Vaccination and Pulmonary Rehabilitation in COPD

What nonpharmacological interventions should one consider for their patients, including vaccination, pulmonary rehabilitation, and lung cancer screening?

Panelists discuss how individualized chronic obstructive pulmonary disease (COPD) maintenance therapy considers symptom severity, exacerbation risk, and eosinophil levels. Dupilumab and ensifentrine require adherence to prescribed dosing for efficacy and safety.

Maintenance Therapy and Adherence to COPD Treatment

What are key considerations when selecting individualized maintenance therapy for COPD?

What are the dosing and administration recommendations for dupilumab and ensifentrine? Is treatment adherence a concern with either agent?

Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.

Ensifentrine (ENHANCE Trials) in COPD

Ensifentrine is recommended in the 2025 GOLD Report as a bronchodilator to improve dyspnea. Ensifentrine is also suggested as a potential anti-inflammatory therapy in stable COPD.

What were the main patient eligibility criteria and clinical outcomes in the ENHANCE trials?

How do you anticipate that ensifentrine will be used in clinical practice (ie, monotherapy, add-on, both)?

Ravi Kalhan, MD, MS

Articles